Skip to main content

Main navigation (without target group)

About FCS
The challenges of FCS
About Waylivra
Getting started
Administration
Patient

Breadcrumb

Home
Administration

Administration

Administration

Footer Menu

Cookie policy
Privacy policy
Terms of use

The information on this website is intended for Healthcare Professionals (HCPs) only

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

© 2022 Swedish Orphan Biovitrum AB (publ)
All rights reserved
Sobi and Waylivra are trademarks of Swedish Orphan Biovitrum AB (publ)
All third party trademarks are the property of their respective owners

Waylivra^® is a registered trademark of Akcea Therapeutics, Inc. Discovered and developed by Ionis Pharmaceuticals and distributed under an agreement with Akcea Therapeutics.

Date of preparation: June 2022. PP-15826

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden
Reg. No. 556038-9321

Tel: +4686972000

Contact see: www.sobi.com